FDA Approves Tukysa for Advanced HER2-positive Breast Cancer

FDA Approves Tukysa for Advanced HER2-positive Breast Cancer
Seattle Genetics Tukysa (tucatinib) can now be used in combination with trastuzumab and Xeloda (capecitabine) to treat people with metastatic or inoperable HER2-positive breast cancer following its approval by the U.S. Food and Drug Administration (FDA).  This will help patients with or without brain metastases who have received one or more prior treatments with HER2-targeted therapies, such as Kadcycla<
Subscribe or to access all post and page content.